embecta has completed its acquisition of Owen Mumford Holdings Limited, a UK-based medical device and drug delivery innovator, in a deal that signals a significant strategic pivot for the US-listed diabetes care company.
The transaction, first announced on 19 March this year, comprises an upfront cash payment of £100m with up to a further £50m in performance-based payments tied to net sales of Owen Mumford's Aidaptus next-generation auto-injector platform during the three years following closing.
Founded in 1952, Owen Mumford brings more than 70 years of healthcare device development experience to the deal, along with an established reputation as a contract partner to pharmaceutical and biotechnology companies.
Its product portfolio spans drug delivery technologies, self-injection devices, diagnostics and broader chronic care applications distributed across global markets.
For embecta, the acquisition accelerates a strategic transformation beyond its core insulin delivery heritage. The company is repositioning itself as a broad-based medical supplies provider, targeting pharmaceutical partners across the obesity, diabetes, autoimmune disease and anaphylaxis markets.
The Aidaptus auto-injector platform — engineered to accommodate a range of drug viscosities and container sizes — is central to that ambition, offering a differentiated capability designed to support complex biologic therapies.
Owen Mumford's device design, moulding and assembly expertise in drug delivery systems will be combined with embecta's global commercial infrastructure, distribution network and large-scale manufacturing capabilities, which the company said in its statement will support both geographic expansion and improved efficiencies.
embecta employs approximately 2500 people globally and has been building toward this kind of platform acquisition since its separation from BD (Becton, Dickinson and Company) in 2022.
The addition of Owen Mumford's intellectual property portfolio will strengthen its position at a time when demand for sophisticated self-injection and drug delivery solutions is rising sharply, driven by the rapid growth of injectable biologics and GLP-1 therapies in metabolic disease.
For Owen Mumford, the acquisition provides access to embecta's international commercial reach, offering a platform to scale its drug delivery technologies beyond its existing pharmaceutical partnerships.